摘要
目的:了解新型冠状病毒肺炎(以下简称新冠肺炎)流行期间乳腺癌患者诊疗情况及心理状态,为今后出现类似突发公共卫生事件时有的放矢,为乳腺癌患者诊疗指导及心理干预提供依据。方法:采用问卷调查法,对全国26省市新冠肺炎疫情前正在接受抗肿瘤治疗的乳腺癌患者疫情期间的诊疗情况及心理状态进行线上问卷调查。采用SPSS 22.0对调查结果进行分析。结果:共收集626份问卷,在被调查的乳腺癌患者中,16.80%的患者西医治疗延迟或中断,其中静脉化疗和靶向治疗受限人数最多;30.85%的患者中医治疗延迟或中断;55.68%的患者复查随访延迟;59.81%的患者西医治疗延迟或中断长达4周及以上。受疫情影响,28.64%的患者出现焦虑和(或)抑郁,达到需要进行心理专科干预者占被调查总人数的12.32%。且在延迟诊疗人群中焦虑和(或)抑郁比例明显高于非延迟治疗人群(33.50%vs 26.70%,P<0.05)。结论:大部分乳腺癌患者诊疗(包括复查随访和治疗)在疫情期间延迟或中断。此外,乳腺癌患者在疫情期间焦虑抑郁比例明显增高,且与治疗延迟相关。因此,在疫情期间及时为患者提供便捷的诊疗指导及心理疏导有助于帮助患者从容应对疫情,减少心理压力,控制乳腺癌发生发展。
Objective:To investigate the treatment status and psychological status of breast cancer patients during the pandemic of COVID-19 in China.Methods:An online cross-sectional survey was conducted between Feburary 2020 and March 2020 in 26 provinces or cities of China.The survey enrolled 626 breast cancer patients in total.The treatment included chemotherapy,endocrine therapy,molecular targeted therapy and traditional Chinese medicine(TCM)and anxiety and depression by using the hospital anxiety and depression survey(HADS).Results:Among all the patients,16.80%had conventional treatment delay,especially intravenous chemo-and targeted therapy.30.85%had Chinese medicine treatment delayed,55.68%of them had the follow up and examination delayed.59.81%of the treatment was delayed for over 4 weeks.In our survey,the proportion of anxiety and or depression was 28.64%.Notably,12.32%of the patients got a score of HADS-anxiety or a score of HADS-depression over 11,which meant they had severe anxiety or depression and need to be intervened by psychologist.And the percentage of anxiety and or depression was higher in patients whose treatment got delayed than those that didn’t get the treatment delayed(33.50%vs 26.70%,P<0.05).Conclusion:Treatment of most of the investigated patients got delayed during the pandemic of COVID-19.And the proportion of the patients underwent anxiety or depression was higher during the pandemic of COVID-19 which was associated with delayed treatment.
作者
陈冬梅
张英
吕灵艳
张静
张磊
万冬桂
Chen Dongmei;Zhang Ying;Lv Lingyan;Zhang Jing;Zhang Lei;Wan Donggui(Department of Integrative Oncology,China-Japan Friendship Hospital,Beijing 100029,China;Beijing University of Chinese Medicine,Beijing 100029,China)
出处
《现代肿瘤医学》
CAS
2020年第12期2179-2182,共4页
Journal of Modern Oncology